Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Patrik Ling as VP of Investor Relations Scandinavia, based in Stockholm. Ling brings over 25 years of life-science industry experience, most recently serving as Senior Equity Analyst at DNB Carnegie where he covered life science companies including Alvotech.
The appointment aligns with Alvotech's strategy to expand its Scandinavian shareholder base and strengthen its position as a leading Nordic life science company. Ling's background spans both pharmaceutical and financial sectors, including roles in marketing, sales, portfolio management, and equity analysis.
Alvotech (NASDAQ: ALVO), azienda biotech globale specializzata in farmaci biosimilari, ha nominato Patrik Ling Vicepresidente delle Relazioni con gli Investitori per la Scandinavia, con base a Stoccolma. Ling vanta oltre 25 anni di esperienza nel settore life science, e proviene dall鈥檌ncarico di Senior Equity Analyst presso DNB Carnegie, dove ha seguito societ脿 del settore, inclusa Alvotech.
La nomina 猫 coerente con la strategia di Alvotech di ampliare la platea di azionisti scandinavi e rafforzare la propria posizione come realt脿 leader nelle life science nordiche. Il profilo di Ling unisce esperienze nei settori farmaceutico e finanziario, con ruoli in marketing, vendite, gestione del portafoglio e analisi azionaria.
Alvotech (NASDAQ: ALVO), compa帽铆a biotecnol贸gica global centrada en medicamentos biosimilares, ha designado a Patrik Ling como vicepresidente de Relaciones con Inversores para Escandinavia, con base en Estocolmo. Ling aporta m谩s de 25 a帽os de experiencia en la industria de ciencias de la vida, procedente de su puesto como Senior Equity Analyst en DNB Carnegie, donde cubri贸 empresas del sector, incluida Alvotech.
El nombramiento encaja con la estrategia de Alvotech de ampliar su base de accionistas en Escandinavia y consolidarse como una de las principales compa帽铆as de ciencias de la vida en la regi贸n n贸rdica. La trayectoria de Ling abarca tanto el 谩mbito farmac茅utico como el financiero, con experiencia en marketing, ventas, gesti贸n de carteras y an谩lisis de acciones.
Alvotech (NASDAQ: ALVO)電� 氚旍澊鞓れ嫓氚�霟� 鞚橃暯頀堨棎 欤茧牓頃橂姅 旮�搿滊矊 氚旍澊鞓ろ厤 旮办梾鞙茧, 鞀ろ啞頇�毽勳潉 瓯办爯鞙茧 頃橂姅 鞀れ垢霐旊倶牍勳晞 雼措嫻 韴瀽鞛愱磤瓿� 攵�靷灔(Patrik Ling)鞚� 鞛勲獏頄堨姷雼堧嫟. Ling鞚� 25雲� 鞚挫儊鞚� 霛检澊頂勳偓鞚挫柛鞀� 靷办梾 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 斓滉芳鞐愲姅 DNB Carnegie鞐愳劀 鞁滊媹鞏� 欤检嫕 鞎犽剱毽姢韸鸽 鞛頃橂┌ Alvotech毳� 韽暔頃� 甏�霠� 旮办梾霌れ潉 雼措嫻頄堨姷雼堧嫟.
鞚措矆 鞛勲獏鞚� 鞀れ垢霐旊倶牍勳晞 欤检＜旄奠潉 頇曤寑頃橁碃 攵侅湢霟� 霛检澊頂勳偓鞚挫柛鞀� 靹犽弰旮办梾鞙茧靹滌潣 鞛呾毳� 臧曧檾頃橂牑電� Alvotech鞚� 鞝勲灥瓿� 攵�頃╉暕雼堧嫟. Ling鞚� 瓴诫牓鞚� 鞝滌暯瓿� 旮堨湹 攵勳暭毳� 鞎勳毎毳措┌, 毵堨紑韺�, 鞓侅梾, 韽姼韽措Μ鞓� 甏�毽� 氚� 欤检嫕 攵勳劃 攵勳暭鞚� 瓴巾棙鞚� 韽暔頃╇媹雼�.
Alvotech (NASDAQ: ALVO), entreprise biotechnologique mondiale sp茅cialis茅e dans les m茅dicaments biosimilaires, a nomm茅 Patrik Ling vice鈥憄r茅sident des relations investisseurs pour la Scandinavie, bas茅 脿 Stockholm. Ling poss猫de plus de 25 ans d鈥檈xp茅rience dans les sciences du vivant et occupait r茅cemment le poste de Senior Equity Analyst chez DNB Carnegie, o霉 il suivait des soci茅t茅s du secteur, dont Alvotech.
Cette nomination s鈥檌nscrit dans la strat茅gie d鈥橝lvotech visant 脿 茅largir sa base d鈥檃ctionnaires scandinaves et 脿 consolider sa position de leader nordique des sciences du vivant. Le parcours de Ling couvre les secteurs pharmaceutique et financier, avec des fonctions en marketing, ventes, gestion de portefeuille et analyse financi猫re.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen mit Schwerpunkt auf Biosimilars, hat Patrik Ling zum Vice President Investor Relations Skandinavien mit Sitz in Stockholm ernannt. Ling verf眉gt 眉ber mehr als 25 Jahre Erfahrung in der Life-Science-Branche und war zuletzt als Senior Equity Analyst bei DNB Carnegie t盲tig, wo er auch Unternehmen wie Alvotech betreute.
Die Ernennung passt zur Strategie von Alvotech, die skandinavische Anteilseignerbasis zu verbreitern und die Position als f眉hrendes nordisches Life-Science-Unternehmen zu st盲rken. Lings Werdegang umfasst sowohl die pharmazeutische als auch die Finanzbranche, mit Stationen in Marketing, Vertrieb, Portfoliomanagement und Aktienanalyse.
- None.
- None.
搁贰驰碍闯础痴滨碍,听ICELAND (August 20, 2025) 鈥� Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm.
Patrik Ling has more than 25 years of experience in the life-science industry. Most recently he served as Senior Equity Analyst at the investment bank DNB Carnegie, covering life science companies, including Alvotech. He began his career in marketing and sales of pharmaceuticals, before transitioning to the financial sector, where he was a portfolio manager and equity analyst focusing on the life-science sector.
鈥淚t is a great pleasure to have Patrik on board, as he鈥檚 been following Alvotech closely over the years and is a highly respected expert within the life science industry in Scandinavia. Patrik鈥檚 background in both pharma and finance, will be a great asset to our team as we continue to broaden our shareholder base in Scandinavia and affirm Alvotech鈥檚 role as a leading life science company in the Nordics,鈥� said R贸bert Wessman, chairman and CEO of Alvotech.聽聽
鈥淭his is a truly exciting time to join Alvotech, with its expanding portfolio of products in the market and in development, supported by a new base of R&D operations in Sweden. Biosimilars play an important role in meeting the growing demand for high-quality biologics and controlling the escalating cost of healthcare. I look forward to engaging with Scandinavian investors, helping them to better understand Alvotech鈥檚 strengths and value proposition,鈥� said Patrik Ling.
About Alvotech
Alvotech is a biotech company, founded by R贸bert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira庐 (adalimumab) and Stelara庐 (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech鈥檚 commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy鈥檚 (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Megalabs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit . None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our , and our or follow us on social media on , , , and .
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
FAQ
Who is the new VP of Investor Relations Scandinavia at Alvotech (NASDAQ: ALVO)?
What is Patrik Ling's background before joining Alvotech (NASDAQ: ALVO)?
Why did Alvotech (NASDAQ: ALVO) appoint a VP of Investor Relations for Scandinavia?
Where will Alvotech's new VP of Investor Relations Scandinavia be based?
